PAGE 1
WES MOORE, Governor Ch. 962

Chapter 962

(House Bill 1056)

AN ACT concerning

State Board of Pharmacy – Prohibition on Discrimination Against 340B Drug
Distribution

FOR the purpose of prohibiting a 340B manufacturer, ~~wholesale~~ ~~drug~~ ~~distributor,~~ ~~or~~
~~third–party~~ ~~logistics~~ ~~provider,~~ ~~or~~ ~~an~~ ~~agent~~ ~~or~~ ~~affiliate~~ ~~of~~ ~~a~~ ~~340B~~ ~~manufacturer,~~
~~wholesale~~ ~~drug~~ ~~distributor,~~ ~~or~~ ~~third–party~~ ~~logistics~~ ~~provider,~~ from taking certain
direct or indirect actions to limit or restrict the acquisition or delivery of a 340B drug;
making a violation of this Act an unfair, abusive, or deceptive trade practice within
the meaning of the Consumer Protection Act; requiring the Maryland Prescription
Drug Affordability Board to conduct a study of the 340B Program; and generally
relating to 340B drugs.

BY repealing and reenacting, with amendments,
Article – Commercial Law
Section 13–301(14)(xl)
Annotated Code of Maryland
(2013 Replacement Volume and 2023 Supplement)

BY repealing and reenacting, without amendments,
Article – Commercial Law
Section 13–301(14)(xli)
Annotated Code of Maryland
(2013 Replacement Volume and 2023 Supplement)

BY adding to
Article – Commercial Law
Section 13–301(14)(xlii)
Annotated Code of Maryland
(2013 Replacement Volume and 2023 Supplement)

BY repealing and reenacting, without amendments,
Article – Health Occupations
Section 12–101(a) and (d)
Annotated Code of Maryland
(2021 Replacement Volume and 2023 Supplement)

BY adding to
Article – Health Occupations
Section 12–6C–09.1
Annotated Code of Maryland
(2021 Replacement Volume and 2023 Supplement)
– 1 –

PAGE 2
Ch. 962 2024 LAWS OF MARYLAND

SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
That the Laws of Maryland read as follows:

Article – Commercial Law

13–301.

Unfair, abusive, or deceptive trade practices include any:

(14) Violation of a provision of:

[or](xl) Title 14, Subtitle 13 of the Public Safety Article;

(xli) Title 14, Subtitle 45 of this article; or

(XLII)SECTION 12–6C–09.1 HEALTH OCCUPATIONSOF THE
ARTICLE; OR

Article – Health Occupations

12–101.

(a) In this title the following words have the meanings indicated.

(d) “Board” means the State Board of Pharmacy.

12–6C–09.1.

(A) (1) IN THIS SECTION THE FOLLOWING WORDS HAVE THE MEANINGS
INDICATED.

(2) “COVERED ENTITY” 42 U.S.C. §HAS THE MEANING STATED IN
256B(A)(4).

(3) “PACKAGE” 21 U.S.C. §HAS THE MEANING STATED IN
360EEE(11).

(4) (I) “340B DRUG” THAT:MEANS A DRUG

1. IS 42 U.S.C. §A COVERED OUTPATIENT DRUG UNDER
256B;

2. HAS BEEN SUBJECT TO AN OFFER FOR REDUCED
340B 42 U.S.C. § 256B(A)(1);PRICES BY A MANUFACTURER UNDER AND

– 2 –

PAGE 3
WES MOORE, Governor Ch. 962

3. IS ENTITY.PURCHASED BY A COVERED

(II) “340B DRUG” INCLUDES A DRUG THAT WOULD HAVE BEEN
~~(D)~~ (C)PURCHASED BUT FOR THE LIMITATION UNDER SUBSECTION OF THIS
SECTION.

(5) “340B MANUFACTURER” MANUFACTURER,MEANS A AS DEFINED
42 U.S.C. § 1396R–8(K)(5),IN OF COVERED OUTPATIENT DRUGS THAT HAS SIGNED
42 U.S.C. § 256B(A)(1).A PHARMACEUTICAL PRICING AGREEMENT UNDER

(B) ~~THIS~~ ~~TO:~~~~SECTION~~ ~~APPLIES~~

~~(1)~~ ~~A~~ ~~340B~~ ~~MANUFACTURER;~~

~~(2)~~ ~~A~~ ~~DISTRIBUTOR;~~~~WHOLESALE~~ ~~DRUG~~

~~(3)~~ ~~A~~ ~~THIRD–PARTY~~ ~~PROVIDER;~~~~LOGISTICS~~ ~~AND~~

~~(4)~~ ~~AN~~ ~~340B~~ ~~MANUFACTURER,~~~~AGENT~~ ~~OR~~ ~~AFFILIATE~~ ~~OF~~ ~~A~~
~~DISTRIBUTOR,~~ ~~THIRD–PARTY~~ ~~PROVIDER.~~~~WHOLESALE~~ ~~DRUG~~ ~~OR~~ ~~LOGISTICS~~

~~(C)~~ THIS BE:SECTION MAY NOT BE CONSTRUED TO

(1) LESS RESTRICTIVE THAN ANY FEDERAL LAW THAT IS APPLICABLE
SECTION;TO A PERSON REGULATED BY THIS OR

(2) IN STATECONFLICT WITH APPLICABLE FEDERAL AND LAWS AND
REGULATIONS.

~~(D)~~ (C) (1) EXCEPT (2)AS PROVIDED IN PARAGRAPH OF THIS
SUBSECTION, 340B~~AN~~ ~~ENTITY~~ ~~SUBJECT~~ ~~TO~~ ~~THIS~~ ~~SECTION~~ A MANUFACTURER MAY
DENY, RESTRICT, PROHIBIT,NOT DIRECTLY OR INDIRECTLY DISCRIMINATE
AGAINST, 340B BY,OR OTHERWISE LIMIT THE ACQUISITION OF A DRUG OR
340B TO,DELIVERY OF A DRUG A PHARMACY THAT IS UNDER CONTRACT WITH OR
340BOTHERWISE AUTHORIZED BY A COVERED ENTITY TO RECEIVE DRUGS ON
340BBEHALF OF THE COVERED ENTITY UNLESS THE RECEIPT OF DRUGS IS
U.S. DEPARTMENT HEALTH HUMAN SERVICES.PROHIBITED BY THE OF AND

(2) ~~AN~~ A 340B~~ENTITY~~ ~~SUBJECT~~ ~~TO~~ ~~THIS~~ ~~SECTION~~ MANUFACTURER
340BMAY LIMIT THE DISTRIBUTION OF A DRUG IF THE LIMITATION IS REQUIRED
21 U.S.C. § 355–1.UNDER

– 3 –

PAGE 4
Ch. 962 2024 LAWS OF MARYLAND

~~(E)~~ (D) (1) (I) A ~~(D)~~ (C)VIOLATION OF SUBSECTION OF THIS
SECTION:

~~(I)~~ 1. SUBJECT (2) SUBSECTION,TO PARAGRAPH OF THIS IS
UNFAIR, ABUSIVE,AN OR DECEPTIVE TRADE PRACTICE WITHIN THE MEANING OF
TITLE 13 COMMERCIAL LAW ARTICLEOF THE AND IS SUBJECT TO THE
TITLE 13ENFORCEMENT AND PENALTY PROVISIONS CONTAINED IN OF THE
COMMERCIAL LAW ARTICLE; AND

~~(II)~~ 2. A. ~~SHALL~~ IF THE ALLEGED VIOLATION WAS
BOARD,COMMITTED BY A PERSON THAT IS LICENSED OR PERMITTED BY THE SHALL
BOARD CONSUMERBE ~~JOINTLY~~ ~~OR~~ ~~SEPARATELY~~ INVESTIGATED BY THE OR THE
PROTECTION DIVISION OFFICE ATTORNEY GENERAL;OF THE OF THE OR

B. IF THE ALLEGED VIOLATION WAS COMMITTED BY A
BOARD,PERSON THAT IS NOT LICENSED OR PERMITTED BY THE SHALL BE
CONSUMER PROTECTION DIVISION OFFICEINVESTIGATED BY THE OF THE OF THE
ATTORNEY GENERAL.

(II) AS PART OF AN INVESTIGATION CONDUCTED UNDER
(1)(I)2 PARAGRAPH, BOARD CONSUMERSUBPARAGRAPH OF THIS THE OR THE
PROTECTION DIVISION OFFICE ATTORNEY GENERALOF THE OF THE MAY
340B MANUFACTURER,INVESTIGATE AN AFFILIATE OR A CONTRACTOR OF THE
THIRD–PARTY PROVIDER.INCLUDING A WHOLESALER OR LOGISTICS

(2) (I) IN TITLE 13ADDITION TO THE PENALTIES UNDER OF THE
COMMERCIAL LAW ARTICLE, A CIVIL FINE MAY BE ASSESSED IN THE AMOUNT OF
~~$50,000~~ $5,000 ~~(D)~~ (C) SECTION.PER VIOLATION OF SUBSECTION OF THIS

(II) A VIOLATION OF THIS SECTION DOES NOT CREATE A
§ 13–408 COMMERCIAL LAW ARTICLE.PRIVATE RIGHT OF ACTION UNDER OF THE

(3) IF ~~(D)~~ (C)A VIOLATION OF SUBSECTION OF THIS SECTION IS
BOARD, BOARDCOMMITTED BY A PERSON LICENSED OR PERMITTED BY THE THE
DISCIPLINE, SUSPENSION, PERSON’SMAY IMPOSE OR REVOCATION OF THE LICENSE
PERMIT.OR

(4) EACH 340BPACKAGE OF DRUGS SUBJECT TO A VIOLATION OF
~~(D)~~ (C) VIOLATION.SUBSECTION OF THIS SECTION SHALL CONSTITUTE A SEPARATE

SECTION 2. AND BE IT FURTHER ENACTED, That:

– 4 –

PAGE 5
WES MOORE, Governor Ch. 962

(a) The Maryland Prescription Drug Affordability Board, in consultation with the
Maryland Department of Health:

(1) shall conduct a study on:

(i) the current implementation and scope of the 340B Program in
the State;

(ii) the implementation and impact of the implementation of Section
1 of this Act; and

(iii) the finances of the Program in the State, including how covered
entities reinvest savings realized from the Program; and

(2) may require covered entities and 340B manufacturers to report
information as necessary to complete the study.

(b) On or before July 1, 2026, the Maryland Prescription Drug Affordability Board
shall report its findings and recommendations from the study to the Senate Finance
Committee and the House Health and Government Operations Committee, in accordance
with § 2–1257 of the State Government Article.

SECTION ~~2.~~ 3. AND BE IT FURTHER ENACTED, That this Act shall take effect
July 1, 2024.

Approved by the Governor, May 16, 2024.

– 5 –